Part 2: Managing Cabozantinib/Nivolumab and other First-Line RCC Regimens - Targeted Oncology

During a live virtual event, Brian Rini, MD, discussed how the combination of cabozantinib plus nivolumab compares with lenvatinib plus pembrolizumab in terms of tolerability and management in patients with advanced renal cell carcinoma.

DISCUSSION QUESTIONS:

• What are your reactions to the CheckMate 9ER (NCT03141177) data? 
• What is your impression of the safety/tolerability of this regimen? 
• Are you familiar … [+8387 chars]
  full article...